Payment overview · 2025
General Payments
$1,168.33
49 reported records · 9 companies
Healthcare provider profile · identity verified
Giosely M Collado, RPAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · NEW YORK, NY · NPI 1649475021
Verified facts
What the public records show
CMS Open Payments records show Giosely M Collado, RPAC received $1,168.33 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $308.54 | 26.4% | 26 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $255.93 | 21.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.91 | 13.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $135.03 | 11.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.44 | 10.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.06 | 5.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.63 | 4.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.62 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.17 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,100.38 | 48 |
| Education | $67.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $255.93 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $177.20 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.91 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $150.56 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.31 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $67.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.16 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.27 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 198 |
| Gabapentin | Gabapentin | 421 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 101 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 325 | 106 |
| Omeprazole | Omeprazole | 302 | 80 |
| Montelukast Sodium | Montelukast Sodium | 297 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 73 |
| Famotidine | Famotidine | 229 | 57 |
| Metformin Hcl Er | Metformin Hcl | 225 | 58 |
| Ezetimibe | Ezetimibe | 223 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 53 |
| Meloxicam | Meloxicam | 211 | 81 |
| Jardiance | Empagliflozin | 174 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 56 |
| Alendronate Sodium | Alendronate Sodium | 171 | 41 |
| Losartan Potassium | Losartan Potassium | 171 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 72 |
| Icosapent Ethyl | Icosapent Ethyl | 164 | 27 |
| Vascepa | Icosapent Ethyl | 159 | 27 |
| Donepezil Hcl | Donepezil Hcl | 158 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 153 | 41 |
| Meclizine Hcl | Meclizine Hcl | 141 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 126 | 27 |
| Ammonium Lactate | Ammonium Lactate | 124 | 41 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 121 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 112 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 50 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 112 | 23 |
| Januvia | Sitagliptin Phosphate | 112 | 24 |
| Azithromycin | Azithromycin | 109 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 30 |
| Carvedilol | Carvedilol | 107 | 27 |
| Linzess | Linaclotide | 99 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 73 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 91 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 25 |
| Tradjenta | Linagliptin | 87 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 38 |
| Metformin Hcl | Metformin Hcl | 82 | 35 |
| Pregabalin | Pregabalin | 82 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 79 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 17 |
| Estradiol | Estradiol | 75 | 34 |
| Prednisone | Prednisone | 75 | 60 |
| Ozempic | Semaglutide | 71 | 17 |
| Ibuprofen | Ibuprofen | 70 | 51 |
| Lisinopril | Lisinopril | 62 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 37 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 17 |
| Enalapril Maleate | Enalapril Maleate | 56 | 19 |
| Single Use Swab | Alcohol Antiseptic Pads | 56 | 14 |
| Eliquis | Apixaban | 54 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 32 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | 35 |
| Trazodone Hcl | Trazodone Hcl | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 49 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 48 | suppressed |
| Valsartan | Valsartan | 48 | 12 |
| Jentadueto | Linagliptin/Metformin Hcl | 46 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 31 |
| Allopurinol | Allopurinol | 40 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Fluconazole | Fluconazole | 39 | 29 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 13 |
| Lidocaine | Lidocaine | 36 | 16 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 36 | 13 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Naproxen | Naproxen | 33 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 14 |
| Mupirocin | Mupirocin | 30 | 28 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | 12 |
| Baclofen | Baclofen | 27 | 16 |
| Metronidazole | Metronidazole | 27 | 24 |
| Ciclopirox | Ciclopirox Olamine | 25 | 12 |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Furosemide | Furosemide | 20 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 19 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 17 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | 11 |
| Promethazine Hcl | Promethazine Hcl | 18 | 14 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,168.33 · 49 records | ABBVIE INC. | APRETUDE, CREON, ELIQUIS, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error